Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?

van Weeghel C, Wierenga APA, Versluis M, van Hall T, van der Velden PA, Kroes WGM, Pfeffer U, Luyten GPM, Jager MJ.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1127. doi: 10.3390/cancers11081127.

2.

Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma.

Dogrusöz M, Ruschel Trasel A, Cao J, Ҫolak S, van Pelt SI, Kroes WGM, Teunisse AFAS, Alsafadi S, van Duinen SG, Luyten GPM, van der Velden PA, Amaro A, Pfeffer U, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1104. doi: 10.3390/cancers11081104.

3.

Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma.

Souri Z, Wierenga APA, van Weeghel C, van der Velden PA, Kroes WGM, Luyten GPM, van der Burg SH, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1102. doi: 10.3390/cancers11081102.

4.

Tumour Angiogenesis in Uveal Melanoma Is Related to Genetic Evolution.

Brouwer NJ, Gezgin G, Wierenga APA, Bronkhorst IHG, Marinkovic M, Luyten GPM, Versluis M, Kroes WGM, van der Velden PA, Verdijk RM, Jager MJ.

Cancers (Basel). 2019 Jul 13;11(7). pii: E979. doi: 10.3390/cancers11070979.

5.

Ischemia Is Related to Tumour Genetics in Uveal Melanoma.

Brouwer NJ, Wierenga APA, Gezgin G, Marinkovic M, Luyten GPM, Kroes WGM, Versluis M, van der Velden PA, Verdijk RM, Jager MJ.

Cancers (Basel). 2019 Jul 18;11(7). pii: E1004. doi: 10.3390/cancers11071004.

6.

Usage of Droplet Digital PCR (ddPCR) Assays for T Cell Quantification in Cancer.

Zoutman WH, Nell RJ, van der Velden PA.

Methods Mol Biol. 2019;1884:1-14. doi: 10.1007/978-1-4939-8885-3_1.

PMID:
30465192
7.

Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.

de Lange MJ, Nell RJ, Lalai RN, Versluis M, Jordanova ES, Luyten GPM, Jager MJ, van der Burg SH, Zoutman WH, van Hall T, van der Velden PA.

Mol Cancer Res. 2018 Dec;16(12):1902-1911. doi: 10.1158/1541-7786.MCR-18-0114. Epub 2018 Aug 9.

PMID:
30093564
8.

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ.

JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729.

9.

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Gezgin G, Dogrusöz M, van Essen TH, Kroes WGM, Luyten GPM, van der Velden PA, Walter V, Verdijk RM, van Hall T, van der Burg SH, Jager MJ.

Cancer Immunol Immunother. 2017 Jul;66(7):903-912. doi: 10.1007/s00262-017-1991-1. Epub 2017 Apr 8.

10.

Accurate Quantification of T Cells by Measuring Loss of Germline T-Cell Receptor Loci with Generic Single Duplex Droplet Digital PCR Assays.

Zoutman WH, Nell RJ, Versluis M, van Steenderen D, Lalai RN, Out-Luiting JJ, de Lange MJ, Vermeer MH, Langerak AW, van der Velden PA.

J Mol Diagn. 2017 Mar;19(2):236-243. doi: 10.1016/j.jmoldx.2016.10.006. Epub 2016 Dec 22.

PMID:
28012713
11.

Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes.

van Essen TH, van Pelt SI, Bronkhorst IH, Versluis M, Némati F, Laurent C, Luyten GP, van Hall T, van den Elsen PJ, van der Velden PA, Decaudin D, Jager MJ.

PLoS One. 2016 Oct 20;11(10):e0164292. doi: 10.1371/journal.pone.0164292. eCollection 2016.

12.

Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Cao J, Heijkants RC, Jochemsen AG, Dogrusöz M, de Lange MJ, van der Velden PA, van der Burg SH, Jager MJ, Verdijk RM.

Oncotarget. 2016 Jul 22;8(35):58021-58036. doi: 10.18632/oncotarget.10770. eCollection 2017 Aug 29.

13.

Embryonic Zebrafish: Different Phenotypes after Injection of Human Uveal Melanoma Cells.

van der Ent W, Burrello C, de Lange MJ, van der Velden PA, Jochemsen AG, Jager MJ, Snaar-Jagalska BE.

Ocul Oncol Pathol. 2015 Apr;1(3):170-81. doi: 10.1159/000370159. Epub 2015 Apr 9. Review.

14.

Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients.

van Dijk EH, Duits DE, Versluis M, Luyten GP, Bergen AA, Kapiteijn EW, de Lange MJ, Boon CJ, van der Velden PA.

Medicine (Baltimore). 2016 May;95(18):e3457. doi: 10.1097/MD.0000000000003457.

15.

PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.

Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW.

Clin Cancer Res. 2016 Mar 1;22(5):1234-42. doi: 10.1158/1078-0432.CCR-15-2071.

16.

Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.

de Lange MJ, van Pelt SI, Versluis M, Jordanova ES, Kroes WG, Ruivenkamp C, van der Burg SH, Luyten GP, van Hall T, Jager MJ, van der Velden PA.

Oncotarget. 2015 Nov 10;6(35):37824-35. doi: 10.18632/oncotarget.5637.

17.

Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism.

de Lange MJ, Razzaq L, Versluis M, Verlinde S, Dogrusöz M, Böhringer S, Marinkovic M, Luyten GP, de Keizer RJ, de Gruijl FR, Jager MJ, van der Velden PA.

PLoS One. 2015 Sep 14;10(9):e0138002. doi: 10.1371/journal.pone.0138002. eCollection 2015.

18.

EMT-associated factors promote invasive properties of uveal melanoma cells.

Asnaghi L, Gezgin G, Tripathy A, Handa JT, Merbs SL, van der Velden PA, Jager MJ, Harbour JW, Eberhart CG.

Mol Vis. 2015 Aug 25;21:919-29. eCollection 2015.

19.

Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.

Versluis M, de Lange MJ, van Pelt SI, Ruivenkamp CA, Kroes WG, Cao J, Jager MJ, Luyten GP, van der Velden PA.

PLoS One. 2015 Mar 12;10(3):e0116371. doi: 10.1371/journal.pone.0116371. eCollection 2015.

20.

Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.

Herlihy N, Dogrusöz M, van Essen TH, Harbour JW, van der Velden PA, van Eggermond MC, Haasnoot GW, van den Elsen PJ, Jager MJ.

Invest Ophthalmol Vis Sci. 2015 Jan 15;56(3):1447-58. doi: 10.1167/iovs.14-15250.

Supplemental Content

Loading ...
Support Center